AbbVie, Bristol-Myers, Pfizer, Roche sales and marketing update

The U.K.’s NICE issued final draft guidance recommending four DMARDs to treat juvenile idiopathic arthritis--their approved indication. The drugs are Enbrel etanercept from Pfizer, Humira adalimumab from AbbVie, Orencia abatacept from Bristol-Myers Squibb, and RoActemra tocilizumab from Roche. ...